RU97105822A - ANALOGUES OF THE GROWTH GROWTH FACTOR - Google Patents

Claims (1)

1. Polypeptide analogue of KGF with modification to 24 first N-terminal amino acids, characterized by the fact that cysteine residues corresponding to the positions of amino acids 1 and 15 of KGF [amino acid positions 32 and 46 of SEQ ID NO: 2, (Cys ¹ and Cys ¹⁵ , respectively) ] removed or replaced by another amino acid. 2. The polypeptide analogue according to claim 1, in which Cys ¹ and Cys ^{15 are} deleted.  3. The polypeptide analogue according to claim 1, in which the first from 15 to 24 N-terminal amino acids are split. 4. The polypeptide analogue according to claim 1, in which Cys ^{1 is} removed and Cys ^{15 is} replaced by another amino acid. 5. The polypeptide analogue according to claim 1, wherein up to fourteen first N-terminal amino acids are cleaved, and Cys ^{15 is} replaced with another amino acid. 6. The polypeptide analogue according to claim 1, in which Cys ¹ and Cys ^{15 are} replaced by another amino acid.  7. Polypeptide analogue according to any one of paragraphs. 4, 5 or 6, in which the cysteine is replaced by an amino acid selected from the group consisting of alanine, leucine and serine.  8. The polypeptide analogue according to claim 7, in which the cysteine is replaced by serine. 9. The polypeptide analogue according to claim 1, selected from the group consisting of C (1,15) S,

10. A pharmaceutical formulation comprising a therapeutically effective amount of a polypeptide analogue according to claim 1 and a pharmaceutically acceptable carrier.  11. A pharmaceutical formulation comprising a therapeutically effective amount of a freeze-dried polypeptide analogue according to claim 1.  12. The pharmaceutical formulation of claim 11, further comprising a pharmaceutically acceptable carrier. 13. A nucleic acid molecule selected from the group consisting of DNA and RNA, in which the nucleic acid molecule encodes a KGF polypeptide analog with up to 24 first N-terminal amino acid modifications, characterized by the fact that cysteine residues correspond to amino acid positions 1 and 15 KGF [provisions amino acids 32 and 46 of SEQ ID NO: 2, (Cys ¹ and Cys ¹⁵ , respectively)], are deleted or replaced by another amino acid. 14. The nucleic acid molecule according to claim 13, encoding a polypeptide analogue of KGF, in which Cys ¹ and Cys ^{15 are} deleted.  15. The nucleic acid molecule according to claim 13, encoding a polypeptide analogue of KGF, in which the first 15 to 24 N-terminal amino acids are cleaved. 16. The nucleic acid molecule according to claim 13, encoding a polypeptide analogue of KGF, in which Cys ^{1 is} removed and Cys ^{15 is} replaced by another amino acid. 17. The nucleic acid molecule according to claim 13, encoding a polypeptide analogue of KGF, in which the first fourteen N-terminal amino acids are cleaved, and Cys ^{15 is} replaced by another amino acid. 18. The nucleic acid molecule according to claim 13, encoding a polypeptide analogue of KGF, in which Cys ¹ and Cys ^{15 are} replaced by another amino acid.  19. The nucleic acid molecule according to any one of paragraphs. 16, 17 or 18, in which cysteine is replaced by an amino acid selected from the group consisting of alanine, leucine and serine.  20. The nucleic acid molecule according to claim 19, in which the codon encoding cysteine is replaced by a codon encoding serine. 21. The nucleic acid molecule according to claim 13, in which the polypeptide analog is selected from the group consisting of C (1,15) S,

22. Biologically functional plasmid or viral vector containing a nucleic acid molecule according to claim 13.  23. A prokaryotic or eukaryotic host cell subjected to a stable transfection or transformation with a biologically functional vector according to claim 22.  24. The prokaryotic host cell of claim 23, which is E. coli.  25. The eukaryotic host cell of claim 23, which is a mammalian cell.  26. The eukaryotic host cell according to claim 25, which is a Chinese hamster ovary cell.  27. A method of producing a KGF polypeptide analogue, consisting in growing a prokaryotic or eukaryotic host cell under the conditions of an appropriate nutrient medium, a stably transformed nucleic acid molecule according to claim 13 in such a way that expression of the encoded polypeptide analog is possible, and isolating the polypeptide produced analogue.  28. A method of stimulating the formation of nefibroblastic epithelial cells, which consists in contacting such cells with an effective amount of the KGF polypeptide analogue according to claim 1.